. They are the largest independent biotech firm. Amgen discovers, develops and
delivers innovative human therapeutics. The company has a manufacturing plant in Longmont,
CO, a distribution center in Louisville, KY, and they have a global government affairs center in
Washington, DC. The name Amgen stands for (Applied Molecular Genetics); this was taken as
the official name of the company in 1983. Amgen has had multiple major corporate acquisitions.
Some of these include: Synergen Inc. (1994), Immunex Corporation (2002), Abgenix Inc.
(2006), and most recently Atlantos Pharmaceutical Holdings Inc. (2007). They have gone
through three chief executive officers since its incorporation in 1980. In 2008 Amgen brought in
a net income of about $3.166 billion, and invested $2.9 billion on R&D.
In the last five years
Amgen’s stock price had an initial value of about $59.18 a share, peaked at 84.86 in early 2005,
then steadily fell to a minimum at $40.11 in early 2008. The minimum stock price in 2008 is
most likely due to the recession. Today the stock price is exactly where it started off five years
ago. The company has shown tremendous growth since its drop in 2008.
Amgen’s principal products in the pharmaceutical field are Aranesp® (darbepoetin alfa),
Enbrel® (etanercept), EPOGEN® (Epoetin alfa), Neulasta® (pegfilgrastim), and NEUPOGEN®
(Filgrastim). Epogen and Neupogen were two of the most successful biopharmaceutical
products of their time. Epogen is a glycoprotein that controls red blood cell production. Epogen
is available as a therapeutic agent produced by
recombinant DNA technology
. It is used in treating
chronic kidney disease
and from the
), and from other critical illnesses (
EPOGEN total sales to date are $1,760 million and it will go off patent in 2009. Neupogen is
used to treat
to stimulate the bone marrow to produce of
Neupogen total sales to date are $1,260 million, and it will go off patent in 2011.
Amgen more than fifty molecules in phase three, there are five that are very new and
innovative. These include Panitumumab, Cinacalcet, Motesaniv, Denosumab, and Darbepoetin
alfa. These are all related to treatment of different types of cancer. They also have multiple